Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.

Yamada Y, Kiyota N, Fuse N, Kato K, Minami H, Hashizume K, Kuroki Y, Ito Y, Ohtsu A.

Gastric Cancer. 2014 Jan;17(1):161-72. doi: 10.1007/s10120-013-0247-9. Epub 2013 Mar 27.

PMID:
23532594
2.

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.

Satoh T, Yamada Y, Muro K, Hayashi H, Shimada Y, Takahari D, Taku K, Nakajima TE, Shi X, Brown KH, Boku N.

Cancer Chemother Pharmacol. 2012 Feb;69(2):439-46. doi: 10.1007/s00280-011-1723-8. Epub 2011 Aug 19.

PMID:
21853311
3.

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.

Koizumi W, Yamaguchi K, Hosaka H, Takinishi Y, Nakayama N, Hara T, Muro K, Baba H, Sasaki Y, Nishina T, Fuse N, Esaki T, Takagi M, Gotoh M, Sasaki T.

Br J Cancer. 2013 Oct 15;109(8):2079-86. doi: 10.1038/bjc.2013.555. Epub 2013 Sep 17. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2382.

4.

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.

Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y.

Invest New Drugs. 2014 Apr;32(2):261-70. doi: 10.1007/s10637-013-9948-5. Epub 2013 May 12.

5.

Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.

Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H.

Ann Oncol. 2015 Sep;26(9):1871-6. doi: 10.1093/annonc/mdv280. Epub 2015 Jun 27.

PMID:
26117830
6.

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group.

Lancet Oncol. 2009 Nov;10(11):1063-9. doi: 10.1016/S1470-2045(09)70259-1. Epub 2009 Oct 7.

PMID:
19818685
7.

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V.

Eur J Cancer. 2013 Nov;49(17):3616-24. doi: 10.1016/j.ejca.2013.07.003. Epub 2013 Jul 27.

PMID:
23899532
8.

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.

Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P.

J Clin Oncol. 2005 Oct 1;23(28):6957-65. Epub 2005 Sep 6.

9.

Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.

Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y.

Radiat Oncol. 2014 Jan 8;9:9. doi: 10.1186/1748-717X-9-9. Erratum in: Radiat Oncol. 2014;9:140.

10.

[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].

Kemmochi T, Egawa T, Mihara Y, Irino T, Ito Y, Nagashima A, Makino H, Yamamuro W.

Gan To Kagaku Ryoho. 2011 Nov;38(12):2351-3. Japanese.

PMID:
22202379
11.

Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.

Tsujitani S, Fukuda K, Kaibara N.

Gastric Cancer. 2003;6 Suppl 1:50-7.

PMID:
12775021
12.

A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.

Kimura Y, Yano H, Imamura H, Fujitani K, Imano M, Tokunaga Y, Matsuoka M, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H.

Jpn J Clin Oncol. 2013 Feb;43(2):125-31. doi: 10.1093/jjco/hys204. Epub 2012 Dec 5.

13.

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.

Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T.

Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18.

14.

[Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].

Koizumi W, Tanabe S, Higuchi K, Sasaki T, Nakayama N, Nagaba S, Azuma M, Shimoda T, Nishimura K, Nakatani K, Saigenji K.

Gan To Kagaku Ryoho. 2004 Nov;31(12):1957-61. Review. Japanese.

PMID:
15570920
15.

[Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].

Hori T, Ikehara T, Takatsuka S, Fukuoka T, Tendo M, Tezuka K, Dan N, Nishino H, Hirakawa K.

Gan To Kagaku Ryoho. 2011 Feb;38(2):293-5. Japanese.

PMID:
21368498
16.

Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.

Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lee J, Yim DS, Lim HY.

Invest New Drugs. 2012 Aug;30(4):1540-7. doi: 10.1007/s10637-011-9706-5. Epub 2011 Jun 22.

PMID:
21695438
17.

Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.

Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T.

Gastric Cancer. 2003;6 Suppl 1:45-9.

PMID:
12775020
18.

A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.

Sato Y, Kondo H, Honda K, Takahari D, Sumiyoshi T, Tsuji Y, Yoshizaki N, Niitsu Y.

Int J Clin Oncol. 2005 Feb;10(1):40-4.

PMID:
15729600
19.

Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.

Nakashima K, Hironaka S, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Kojima T, Machida N.

Jpn J Clin Oncol. 2008 Dec;38(12):810-5. doi: 10.1093/jjco/hyn109. Epub 2008 Nov 6.

20.

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA.

Cancer. 2007 Jan 1;109(1):33-40.

Items per page

Supplemental Content

Write to the Help Desk